六味五灵片联合替比夫定治疗活动性慢性乙型肝炎肝硬化临床疗效观察

目的观察六味五灵片联合替比夫定治疗活动性慢性乙型肝炎（CHB）肝硬化的临床疗效。方法将72例HBV DNA、HBeAg阳性的CHB肝硬化患者随机分为治疗组和对照组,两组均为36例。治疗组给予六味五灵片联合替比夫定治疗,对照组单用替比夫定治疗,疗程均为24周。治疗前后分别检测患者肝功能、慢性HBV标志物、HBV DNA低于检测下限的比率。结果治疗组血清ALT、AST下降明显,与对照组比较,差异有统计学意义（P〈0.05）,治疗组HBeAg低于检测下限的比率及HBeAg/抗-HBe血清转换率均高于对照组,治疗组总有效率高于对照组,差异有统计学意义（P〈0.05）。结论六味五灵片联合替比夫定治疗活动性CHB肝硬化疗效显著,不良反应发生率小,疗效优于单一用药组,是治疗活动性CHB肝硬化的有效方法。

Clinical effect on combination of Liuweiwuling tablets and telbivudinein for patients with cirrhosis induced by active hepatitis B

Objective To observe the clinical effect of Liuweiwuling tablet combined with telbivudine in chronic patients with active hepatitis B related cirrhosis. Methods Total of 72 patients with active hepatitis B related cirrhosis were randomly divided into two groups, the treatment group (n = 36) received Liuweiwuling tablet combined with telbivudine; meanwhile the control group (n = 36) received only telbivudine. Both groups were treated for 24 weeks. Liver function, hepatitis B virus markers and undetectable rate of HBV DNA were tested before and after treatment. Results Compared with the control group, serum ALT and AST levels in the treatment group decreased significantly and there was statistical difference between the two groups (P < 0.05). The undetectable rate of HBeAg, seroconversion rate of HBeAg/anti-HBe and the total effective rate in the treatment group were higher than that in the control group (P < 0.05). Conclusions Liuweiwuling tablet combined with telbivudine therapy is more effective than telbivudine only for patients with active hepatitis B related cirrhosis and with lower incidence of adverse reactions. This combination therapy is an effective way for treating active hepatitis B related cirrhosis patients.